Capricor Therapeutics Inc (CAPR) stock surged on Tuesday after the company announced its intention to file a biologics license application (BLA) with the FDA for full approval of Deramiocel, a potential treatment for Duchenne muscular dystrophy (DMD) cardiomyopathy. This move follows positive discussions with the FDA and builds on promising results from previous clinical trials.